Practical Challenges and Factors Linked to Success in GLP-1 Receptor Agonist Treatment
Updated
Abstract
Real-world discontinuation rates of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing type 2 diabetes and obesity are higher than those reported in clinical trials.
- GLP-1 receptor agonists have shown strong effectiveness in controlling blood sugar levels and aiding weight loss.
- These medications also have potential cardiovascular benefits.
- Discrepancies exist between the success rates observed in clinical trials and those seen in everyday clinical practice.
- Higher discontinuation rates in real-world settings may indicate challenges in maintaining treatment adherence.
Simplified